Pentraxin 3 levels in psoriasis, their relationship with disease severity and the efficacy of narrow-band ultraviolet B therapy Psoriasiste pentraxin 3 düzeyi: Hastalik şiddeti ile ilişkisi ve darband ultraviyole B tedavisinin etkisi
Turkderm Deri Hastaliklari ve Frengi Arsivi, cilt.49, sa.4, ss.263-265, 2015 (Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 49 Sayı: 4
- Basım Tarihi: 2015
- Doi Numarası: 10.4274/turkderm.94468
- Dergi Adı: Turkderm Deri Hastaliklari ve Frengi Arsivi
- Derginin Tarandığı İndeksler: Scopus, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.263-265
- Anahtar Kelimeler: Psoriasis, pentraxin 3, narrowband ultraviolet B
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Background and Design: Pentraxin 3 (PTX 3), an acute phase protein, plays an important role in activation of innate immunity and in the regulation of inflammatory reactions. Thus, considering the importance of PTX 3 in immune and inflammatory responses, it has been suggested that PTX 3 may play a role in the pathogenesis of psoriasis. The aim of this study was to evaluate plasma PTX 3 levels in patients with psoriasis and their relationship with the disease severity and the effect of narrowband ultraviolet B (nbUVB) therapy on PTX 3 levels. Materials and Methods: The study comprised 40 patients with psoriasis and 88 age-and sex-matched healthy controls. Dermatological examinations and psoriasis area severity index (PASI) were performed. The patients received 20 courses of nbUVB therapy with a mean value of 13 joule/cm2. The efficacy of nbUVB was evaluated using PASI scores. Plasma PTX 3 levels in the patient group were measured before and after therapy by sandwich enzyme-linked immunosorbent assay in patients with the diagnosis of psoriasis and were compared with that in the control group. Results: The mean plasma PTX3 level in the patient group (1.24±0.83) was statistically significantly increased compared to that in the control group (0.55±0.26) (p<0.05). A statistically significant decrease in PASI scores were observed after nbUVB therapy (p<0.05). The mean pretreatment plasma PTX 3 level in patients with psoriasis (1.24±0.83) statistically significantly decreased after treatment (0.84±0.62) (p<0.05). Furthermore, the mean post-treatment plasma PTX 3 level in the patient group (0.84±0.62) was significantly higher than in healthy controls (0.55±0.62) (p<0.05). There was no relationship of plasma PTX 3 levels with disease severity, family history, nail involvement, gender, age, and duration of disease (p>0.05). Conclusion: We found that plasma PTX3 levels that are increased in patients with psoriasis were not correlated with disease severity and that they significantly decreased after nbUVB therapy.